Eli Lilly and Company (NYSE:LLY) will release its third quarter earnings report before the opening bell on Thursday, Oct. 29.
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings of $6.67 per share, down from $7.02 per share in the year-ago period. The consensus estimate for LLY’s quarterly revenue is $22.62 billion. It reported $17.6 billion last year, according to Benzinga Pro.
Eli Lilly, on Oct. 15, revealed new data demonstrating that Omvoh (mirikizumab-mrkz) helps patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease achieve multiple simultaneous treatment goals at one year.
Shares of Eli Lilly rose 0.2% to close at $1,281.91 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Leerink Partners analyst David Risinger maintained the stock with an Outperform rating and raised the price target from $1,309 to $1,316 on Oct. 21, 2026. This analyst has an accuracy rate of 78%.
- RBC Capital analyst Trung Huynh reiterated the stock with an Outperform rating and maintained a $1,500 price target on Oct. 12, 2026. This analyst has an accuracy rate of 73%.
- Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $1,410 to $1,440 on Oct. 8, 2026. This analyst has an accuracy rate of 69%.
- Morgan Stanley analyst Terence Flynn maintained the stock with an Overweight rating and lifted the price target from $1,419 to $1,430 on Oct. 7, 2026. This analyst has an accuracy rate of 73%.
- TD Cowen analyst Steve Scala reiterated the stock with a Buy and maintained a $1,250 price target on Sept. 22, 2026. This analyst has an accuracy rate of 70%.
Photo via Shutterstock